OptimizeRx Shares Outstanding History (OPRX)
OptimizeRx reported 18.8M shares outstanding at the end of fiscal 2025.
View full OptimizeRx company overviewOptimizeRx annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 18.8M | 306,289 | +1.66% |
| 2024 | 2024-12-31 | 18.5M | 164,729 | +0.90% |
| 2022 | 2022-12-31 | 18.3M | 427,596 | +2.39% |
| 2021 | 2021-12-31 | 17.9M | 2.6M | +17.33% |
| 2020 | 2020-12-31 | 15.2M | 613,761 | +4.20% |
| 2019 | 2019-12-31 | 14.6M | 2.6M | +21.36% |
| 2018 | 2018-12-31 | 12.0M | 2.3M | +23.19% |
| 2017 | 2017-12-31 | 9.8M | −19.9M | −67.12% |
| 2016 | 2016-12-31 | 29.7M | 687,942 | +2.37% |
| 2015 | 2015-12-31 | 29.0M | 6.2M | +26.95% |
| 2014 | 2014-12-31 | 22.9M | 8.0M | +54.33% |
| 2013 | 2013-12-31 | 14.8M | — | — |
OptimizeRx quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 18.8M | 276,845 | +1.49% |
| Q1 2026 | 2026-03-31 | 18.8M | 272,286 | +1.47% |
| Q4 2025 | 2025-12-31 | 18.8M | 306,289 | +1.66% |
| Q3 2025 | 2025-09-30 | 18.6M | 411,960 | +2.27% |
| Q2 2025 | 2025-06-30 | 18.6M | 169,071 | +0.92% |
| Q1 2025 | 2025-03-31 | 18.5M | 116,018 | +0.63% |
| Q4 2024 | 2024-12-31 | 18.5M | 121,789 | +0.66% |
| Q1 2024 | 2024-03-31 | 18.2M | −108,089 | −0.59% |
| Q3 2023 | 2023-09-30 | 18.4M | 125,681 | +0.69% |
| Q2 2023 · Jun 30 | 2023-06-30 | 18.4M | 202,589 | +1.11% |
| Q1 2023 | 2023-03-31 | 18.3M | 428,903 | +2.40% |
| Q4 2022 | 2022-12-31 | 18.3M | 427,596 | +2.39% |
| Q3 2022 | 2022-09-30 | 18.3M | 533,470 | +3.01% |
| Q2 2022 | 2022-06-30 | 18.2M | 678,753 | +3.88% |
| Q1 2022 | 2022-03-31 | 17.9M | 642,020 | +3.72% |
| Q4 2021 | 2021-12-31 | 17.9M | 2.6M | +17.33% |
| Q3 2021 | 2021-09-30 | 17.7M | 2.7M | +17.62% |
| Q2 2021 | 2021-06-30 | 17.5M | 2.7M | +18.59% |
| Q1 2021 | 2021-03-31 | 17.3M | 2.6M | +17.85% |
| Q4 2020 | 2020-12-31 | 15.2M | 622,761 | +4.27% |
| Q3 2020 | 2020-09-30 | 15.1M | 898,376 | +6.34% |
| Q2 2020 | 2020-06-30 | 14.8M | 635,861 | +4.50% |
| Q1 2020 | 2020-03-31 | 14.6M | 2.4M | +19.28% |
| Q4 2019 | 2019-12-31 | 14.6M | 2.6M | +21.28% |
| Q3 2019 | 2019-09-30 | 14.2M | 2.2M | +18.40% |
| Q2 2019 | 2019-06-30 | 14.1M | 2.6M | +22.15% |
| Q1 2019 | 2019-03-31 | 12.3M | −17.4M | −58.57% |
| Q4 2018 | 2018-12-31 | 12.0M | −17.3M | −58.94% |
| Q3 2018 | 2018-09-30 | 12.0M | −17.3M | −59.11% |
| Q2 2018 | 2018-06-30 | 11.6M | −17.7M | −60.50% |
| Q1 2018 | 2018-03-31 | 29.6M | −100,786 | −0.34% |
| Q4 2017 · Dec 31 | 2017-12-31 | 29.3M | −400,786 | −1.35% |
| Q3 2017 | 2017-09-30 | 29.3M | −397,015 | −1.34% |
| Q2 2017 | 2017-06-30 | 29.3M | −6,577 | −0.02% |
| Q1 2017 | 2017-03-31 | 29.7M | 694,192 | +2.39% |
| Q4 2016 | 2016-12-31 | 29.7M | 687,942 | +2.37% |
| Q3 2016 | 2016-09-30 | 29.7M | 653,707 | +2.25% |
| Q2 2016 | 2016-06-30 | 29.3M | 6.3M | +27.51% |
| Q1 2016 | 2016-03-31 | 29.0M | 6.1M | +26.69% |
| Q4 2015 | 2015-12-31 | 29.0M | 6.2M | +26.95% |
| Q3 2015 | 2015-09-30 | 29.0M | 5.7M | +24.21% |
| Q2 2015 | 2015-06-30 | 22.9M | 8.1M | +54.88% |
| Q1 2015 | 2015-03-31 | 22.9M | — | — |
| Q4 2014 | 2014-12-31 | 22.9M | — | — |
| Q3 2014 | 2014-09-30 | 23.4M | — | — |
| Q4 2013 | 2013-12-31 | 14.8M | — | — |
OptimizeRx shares outstanding trends
Over the last five reported fiscal years, OptimizeRx's shares outstanding moved from 14.6M to 18.8M, a change of 4.2M. The latest reported quarter, Q2 2026, shows 18.8M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review OptimizeRx filings at SEC.gov ↗